<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 19, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00826579</url>
  </required_header>
  <id_info>
    <org_study_id>Rhein4031</org_study_id>
    <nct_id>NCT00826579</nct_id>
  </id_info>
  <brief_title>Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer</brief_title>
  <official_title>Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a feasibility and validation study of the sentinel lymph node (SLN) procedure
      in all stages of colon cancer. If the SLN can be reliably identified, it could be submitted
      to a more accurate histopathological examination (multiple sections, special staining). The
      detection of micrometastases in the SLN (occult stage III, upstaging) is possible. Patients
      with micrometastases should be considered at higher risk.

      Additionally, a search for occult metastatic tumor cells in the bone marrow is performed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>To assess the extent of upstaging due to the SLN procedure for colon cancer.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the accuracy of the SLN procedure for colon cancer. To identify factors influencing the success of the procedure. To correlate SLN results with the presence of colon cancer cell in bone marrow aspirates. To assess OS and DFS.</measure>
    <time_frame>1 month, 3 and 5 years after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colonic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Colon cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colon cancer patients of all stages</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel lymph node procedure</intervention_name>
    <description>After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.</description>
    <arm_group_label>Colon cancer</arm_group_label>
    <other_name>Lymphazurin 1%, Ben Venue Labs Inc., Bedford OH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow aspiration</intervention_name>
    <description>Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.</description>
    <arm_group_label>Colon cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Colon cancer at any stage diagnosed histologically or high degree of suspicion for
             colon cancer at endoscopy, which cannot be confirmed with certainty in the biopsy.
             The diagnosis of cancer must be certain in the definitive histology.

          -  Possibility of transabdominal injection of the dye (cancers below the peritoneal
             reflection in which the injection of dye must be carried out through rectoscopy, are
             therefore excluded).

          -  Patient's informed consent

        Exclusion Criteria:

          -  Prior intrabdominal tumor surgery

          -  Other preexisting malignancies

          -  Hypersensitivity/allergy to dye (isosulfan blue)

          -  Pregnancy

          -  Breast-feeding

          -  No patient's informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten T. Viehl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Zuber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Olten</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carsten T. Viehl, MD</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urban Laffer, MD</name>
      <address>
        <city>Biel</city>
        <zip>2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markus Zuber, MD</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <lastchanged_date>January 20, 2009</lastchanged_date>
  <firstreceived_date>January 13, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Carsten T. Viehl, MD</name_title>
    <organization>University Hospital, Basel, Switzerland</organization>
  </responsible_party>
  <keyword>Sentinel lymph node</keyword>
  <keyword>Lymph node analysis</keyword>
  <keyword>Bone marrow analysis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
